医学界风湿频道|2020ASN前瞻|慢性肾病负担沉重,新型MRA药物能否带来突破?( 二 )


[1] 葛均波 , 徐永健 , 王辰.第9版内科学.[2] GBD Chronic Kidney Disease Collaboration. Lancet 2020;395:709-733.[3] Zhang Luxia, Long Jianyan, Jiang Wenshi, et al. Trends in Chronic Kidney Disease in China.. 2016, 375(9):905-6.[4] Alicic RZ, et al. Clin J Am Soc Nephrol 2017;12:2032–2045.[5] Mora-Fernández C, et al. J Physiol2014;18:3997.[6] Bauersachs J, et al. Hypertension 2015;65:257-263.[7] Niewczas MA, et al. Nat Med 2019;25:805–813.[8] Tofte N, et al. Lancet Diabetes Endocrinol 2020;8:301–312.[9] Kolkhof P, et al. Handb Exp Pharmacol 2017;243:271–305.[10] Barrera-Chimal J, et al. Kidney Int 2019;96:302–319.[11] Buonaf ine M, et al. Am J Hypertension 2018;31:1165–1174.[12] Biw er LA, et al. Am J Hypertension 2019;32:123–134.[13] Amazit L, et al. J Biol Chem 2015;290:21876–21889.[14] Grune J, et al. J Cardiovasc Pharmacol 2016;67:402–411.[15] Grune J, et al. Hypertension 2018;71:599–608.[16] Kolkhof P, et al. J Cardiovasc Pharm 2014;64:69–78.[17] Pitt B, et al. Eur J Heart Fail 2012;14:668–675.[18] kolkhof P, et al. Handb Exp Pharmacol. 2017;243:271-305.[19] Sica DA. Heart Fail Rev 2005;10:23–29.[20] B?rfacker L, et al. ChemMedChem 2012;7:1385–1403.[21] Pitt B, et al. Eur Heart J 2013;34:2453–2463.[22] Bakris GL, et al. JAMA 2015;314:884–894.[23] Filippatos G, et al. Eur Heart J 2016;37:2105–2114.[24] Kolkhof P, et al. Curr Opin Nephrol Hypertens 2015;24:417–424.MA-M_FIN-CN-0002-1


推荐阅读